For decades, malaria control rested on two pillars: killing the mosquito vector and treating the infection once it appeared. A malaria vaccine was the long-sought third pillar, and as of 2026 there are two of them in active use across Africa. RTS,S/AS01 and R21/Matrix-M are not interchangeable products with the same story stamped twice — they differ in efficacy profile, dosing schedule, and rollout trajectory, and understanding those differences matters for anyone tracking how vector-borne disease control is actually changing on the ground.
Two vaccines, one parasite
Both RTS,S/AS01 (marketed as Mosquirix) and R21/Matrix-M target Plasmodium falciparum, the parasite species responsible for the overwhelming majority of malaria deaths, and both work by prompting an immune response against the same circumsporozoite protein on the parasite’s surface. RTS,S was the first malaria vaccine ever to receive a World Health Organization recommendation, in October 2021, following field data from a pilot implementation program. R21/Matrix-M followed two years later, recommended by WHO in October 2023 on the advice of its Strategic Advisory Group of Experts on Immunization and Malaria Policy Advisory Group, and added to the WHO list of prequalified vaccines that December. Having two independently developed, independently recommended products is itself notable: it means supply is not dependent on a single manufacturer, which has historically been a chokepoint for vaccines used almost exclusively in lower-income countries.
Efficacy: what the trial data actually show
Neither vaccine offers anything close to complete protection, and that distinction matters for how each is deployed. In Phase 3 trials, RTS,S showed approximately 39% efficacy against clinical malaria illness and a 30% reduction in severe malaria among infants; a separate pilot analysis found a 55.8% reduction in uncomplicated malaria among children aged 5 to 17 months over 14 months of follow-up. R21/Matrix-M has generally reported higher headline efficacy figures in its own trials — around 75% against symptomatic malaria over 12 months in areas with highly seasonal transmission, and roughly 68% in areas with year-round transmission, with one analysis reporting 72% efficacy across seasonal and standard sites. Because the two vaccines have not been tested head-to-head in the same populations under identical conditions, these figures describe two separate bodies of evidence rather than a controlled comparison — a caveat any operational research desk should carry forward before treating one number as simply better than the other.
| Factor | RTS,S/AS01 (Mosquirix) | R21/Matrix-M |
|---|---|---|
| WHO recommendation | October 2021 | October 2023 |
| Reported efficacy (trial-dependent) | ~39% against clinical illness; ~30% reduction in severe malaria | ~68–75% against symptomatic malaria depending on transmission pattern |
| Primary dosing | Three doses one month apart, plus a booster 12–18 months later | Three-dose regimen with a booster option; some programs use a four-dose schedule |
| Target age | From 5 months, moderate-to-high transmission settings | 5–36 months, moderate-to-high transmission settings |
| First national rollout | Ghana, Kenya, Malawi (pilot, 2019) | Côte d’Ivoire (July 2024) |
Dosing schedule and what it means for coverage
Both vaccines require multiple doses, which is where a vaccine’s real-world value is often won or lost — a vaccine with strong trial efficacy still under-delivers if a program cannot get children back for the third or fourth dose. RTS,S follows a four-dose schedule: three primary doses given one month apart, followed by a booster roughly 12 to 18 months later, though the exact timing has varied slightly by country, with first doses given at 5 or 6 months and boosters as late as 22 to 24 months. R21/Matrix-M is generally described as a three-dose primary series with a booster option, though implementation varies: Uganda, for instance, is administering a four-dose regimen at 6, 7, 8, and 18 months. Programs layering a new multi-dose vaccine onto an already-stretched routine immunization calendar face a genuine operational question, not just a procurement one — each additional contact point is another chance for a caregiver to miss the visit.
Rollout status: where each vaccine actually stands
The rollout timelines diverge sharply from the recommendation dates. RTS,S has the longer track record: Ghana, Kenya, and Malawi began delivering it in 2019 through the Malaria Vaccine Implementation Programme, and more than 1.7 million children in those three countries had received it before Cameroon became the first country to launch it outside a pilot or trial setting, in January 2024. R21/Matrix-M moved faster once recommended, aided by a larger manufacturing base: Côte d’Ivoire launched it in July 2024, and Uganda’s March 2025 campaign — distributing over 2.2 million doses across 105 districts to reach 1.1 million children under two — has been described as the largest single malaria vaccine rollout on the continent to date. By July 2026, roughly 25 African countries had introduced one or both vaccines nationally or subnationally, with Ethiopia notable for pairing R21/Matrix-M with insecticide-treated bed net distribution rather than deploying the vaccine as a standalone intervention.
Reading the comparison correctly
The temptation, especially in a field-procurement or funding context, is to treat this as a horse race with a winner. That framing misses the more consequential point: neither vaccine is a replacement for bed nets, indoor spraying, or case management — both were tested and are deployed as an additive layer on top of existing vector-control measures, not a substitute for them. Supply constraints, not efficacy differences, have driven much of the actual country-level choice between the two products; at least 30 countries had expressed interest in a malaria vaccine with only a fraction able to secure allocation in the near term. For a desk covering vector-borne disease control, the more useful question than "which vaccine is better" is whether a given country’s rollout is layered onto, rather than substituted for, the vector-control and case-management infrastructure that has done most of the work reducing malaria mortality over the past two decades.